cryptotanshinone has been researched along with Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Debnath, B; Neamati, N; Xu, S | 1 |
| Fu, DJ; Li, J; Yu, B | 1 |
| Song, Y; Wang, S; Yang, X; Yu, B; Zhao, M | 1 |
| Abdolvahabi, Z; Deravi, N; Imani, H; Noori, S; Nourbakhsh, M; Salehi, N | 1 |
| Ashrafizadeh, M; Hushmandi, K; Najafi, M; Orouei, S; Saberifar, S; Salami, S; Zarrabi, A | 1 |
| Bittner, ML; Datta, A; Hua, J; Lopes, R; Sima, C; Wilson-Robles, H | 1 |
| Chang, CC; Ho, TF; Huang, LR; Lai, JS; Liao, EC; Lin, JY; Lu, CH; Ma, SW; Tsai, CS | 1 |
| Cao, HH; Cheng, CY; Chow, KY; Fong, WF; Kwan, HY; Tse, AK; Wu, YC; Yu, H; Yu, ZL; Zhu, GY | 1 |
| Chen, W; Fan, F; Li, J; Liu, Z; Lu, Y; Shen, C; Shen, D; Sheng, X; Shi, P; Tao, L; Tian, C; Wang, A; Wei, Z; Zhao, Q; Zhao, Y; Zhou, L; Zhu, P; Zhu, Z | 1 |
| Chen, G; Chen, W; Liu, Y; Lu, Y; Ni, W; Pan, Y; Wang, A; Wang, S; Zhou, L | 1 |
| Chen, W; Han, X; Huang, S; Liu, L; Liu, Z; Lu, Y; Luo, Y; Shen, T; Xu, B; Zhou, H | 1 |
| Awate, S; Chen, W; Huang, S; Liu, L; Lu, Y; Luo, Y; Odaka, Y; Shen, T; Zheng, S; Zhou, H | 1 |
| Chen, G; Chen, W; Huang, S; Lu, Y | 1 |
5 review(s) available for cryptotanshinone and Neoplasms
| Article | Year |
|---|---|
Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; High-Throughput Screening Assays; Humans; Neoplasms; Peptides; Peptidomimetics; Psoriasis; Signal Transduction; STAT3 Transcription Factor; Stem Cells; Structure-Activity Relationship | 2012 |
Annual review of LSD1/KDM1A inhibitors in 2020.
Topics: Antineoplastic Agents, Phytogenic; Enzyme Inhibitors; Histone Demethylases; Humans; Molecular Structure; Neoplasms | 2021 |
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Enzyme Inhibitors; Humans; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2022 |
Recent advances and future directions in anti-tumor activity of cryptotanshinone: A mechanistic review.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Phenanthrenes | 2021 |
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Drugs, Chinese Herbal; Humans; Neoplasms; Phenanthrenes; Phenanthrolines; Salvia miltiorrhiza; TOR Serine-Threonine Kinases | 2013 |
8 other study(ies) available for cryptotanshinone and Neoplasms
| Article | Year |
|---|---|
Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer.
Topics: Animals; Flavanones; Lymphocyte Activation; Mice; Neoplasms; Phenanthrenes; T-Lymphocytes, Regulatory | 2022 |
Comprehensive live-cell imaging analysis of cryptotanshinone and synergistic drug-screening effects in various human and canine cancer cell lines.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dogs; Early Detection of Cancer; Humans; Neoplasms; Phenanthrenes; Salvia miltiorrhiza; Signal Transduction; STAT3 Transcription Factor | 2021 |
Proapoptotic and TRAIL-sensitizing constituents isolated from Salvia militiorrhiza (Danshen).
Topics: Abietanes; Amino Acid Chloromethyl Ketones; Apoptosis; Caspase Inhibitors; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Humans; Inhibitory Concentration 50; Neoplasms; Phenanthrenes; Phenanthrolines; Plant Extracts; Poly(ADP-ribose) Polymerases; Salvia miltiorrhiza; TNF-Related Apoptosis-Inducing Ligand | 2013 |
The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Neoplasms; Phenanthrenes; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Salvia miltiorrhiza; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Up-Regulation | 2013 |
Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Cytoplasm; ELAV-Like Protein 1; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Mice; Neoplasms; Phenanthrenes; RNA Stability; RNA, Messenger; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays; Zebrafish | 2016 |
Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Topics: Adenylate Kinase; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Neoplasms; Phenanthrenes; Phosphorylation; Signal Transduction; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2017 |
Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation.
Topics: Antineoplastic Agents; Cell Proliferation; Cyclin D1; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phenanthrenes; Phosphorylation; Protein Kinases; Retinoblastoma Protein; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2010 |
Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells.
Topics: Antineoplastic Agents, Phytogenic; Caspases; Cell Death; Cell Line, Tumor; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms; p38 Mitogen-Activated Protein Kinases; Phenanthrenes; Up-Regulation | 2012 |